They observed that melanoma patients with eosinophilia at any point in the course of their disease showed a trend toward longer survival, regardless of their therapy ( 35 ). 3.2 Eosinophilic granulocytes and anti-PD1 monotherapy (pembrolizumab, nivolumab) In a recent study by Bai et al.
← all excerpts
Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma.
1
—
—